Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: Correlation with tissue insulin levels

International Journal of Oncology

Volumn 30, Issue 1, 2007, Pages 73-80

  Radulescu, Razvan T ^a   Hufnagel, Carla ^a   Luppa, Peter ^a   Hellebrand, Heide ^a   Kuo, Wen Liang ^b   Rosner, Marsha Rich ^b   Harbeck, Nadia ^a   Giersig, Cecylia ^c   Meindl, Alfons ^a   Schmitt, Manfred ^a   Weirich, Gregor ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Gordon Center for Integrative Science   (United States)

^c Federal Institute for Drugs and Medical Devices   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

10q23 genetic locus; Breast cancer; Immunoassay; Immunohistochemistry; Insulin; Insulin degrading enzyme; Loss of heterozygosity analysis; Normal breast; Tumor marker; Zinc metalloprotease

Indexed keywords

ESTROGEN RECEPTOR; INSULIN; INSULINASE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST; BREAST TUMOR; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MENOPAUSE; METABOLISM; MIDDLE AGED; REFERENCE VALUE;

ADULT; AGED; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULYSIN; MENOPAUSE; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REFERENCE VALUES;

EID: 34548751732     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.1.73     Document Type: Article

References (52)

1. Boyle P and Ferlay J: Cancer incidence and mortality, 2004. Ann Oncol 16: 481-488, 2005.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang C-S, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Süto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS and Gelber RD: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005. (Pubitemid 41464705)
3. Osborne CK, Bolan G, Monaco ME and Lippman ME: Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci USA 73: 4536-4540, 1976.
4. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML and Draznin B: Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 276: 38023-38028, 2001.
5. Castro A, Ziegels-Weissman J, Buschbaum P, Voigt W, Morales A and Nadji M: Immunochemical demonstration of immunoreactive insulin in human breast cancer. Res Commun Chem Pathol Pharmacol 29: 171-182, 1980. (Pubitemid 10082341)
6. Spring-Mills EJ, Stearns SB, Numann PJ and Smith PH: Immunocytochemical localization of insulin- and somatostatin-like material in human breast tumors. Life Sci 35: 185-190, 1984. (Pubitemid 14115230)
7. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas J, Hartwick W, Hoffman B and Hood N: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20: 42-51, 2002.
8. White MF: Insulin signaling in health and disease. Science 302: 1710-1711, 2003.
9. Goldfine ID and Smith GJ: Binding of insulin to isolated nuclei. Proc Natl Acad Sci USA 73: 1427-1431, 1976.
10. Miller DS: Stimulation of RNA and protein synthesis by intracellular insulin. Science 240: 506-509, 1988.
11. Radulescu RT and Wendtner CM: Proposed interaction between insulin and retinoblastoma protein. J Mol Recognit 5: 133-137, 1992.
12. Radulescu RT, Bellitti MR, Ruvo M, Cassani G and Fassina G: Binding of the LXCXE insulin motif to a hexapeptide derived from retinoblastoma protein. Biochem Biophys Res Commun 206: 97-102, 1995.
13. Radulescu RT: From insulin, retinoblastoma protein and the insulin receptor to a new model on growth factor specificity: the nucleocrine pathway. J Endocrinol 146: 365-368, 1995.
14. Radulescu RT, Doklea E, Kehe K and Mückter H: Nuclear colocalization and complex formation of insulin with retinoblastoma protein in HepG2 human hepatoma cells. J Endocrinol 166: R1-R4, 2000.
15. Affholter JA, Fried VA and Roth RA: Human insulin-degrading enzyme shares structural and functional homologies with Escherichia coli protease III. Science 242: 1415-1418, 1988.
16. Harada S, Smith RM, Smith JA and Jarett L: Inhibition of insulin-degrading enzyme increases translocation of insulin to the nucleus in H35 rat hepatoma cells- evidence of a cytosolic pathway. Endocrinology 132: 2293-2298, 1993.
17. Affholter JA, Hsieh CL, Francke U and Roth RA: Insulin-degrading enzyme: stable expression of the human complementary DNA, characterization of its protein product, and chromosomal mapping of the human and mouse genes. Mol Endocrinol 4: 1125-1135, 1990. (Pubitemid 120023686)
18. Qin L-X: Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol 8: 769-776, 2002.
19. Bostrom J, Cobbers JM, Wolter M, Tabatabai G, Weber RG, Lichter P, Collins VP and Reifenberger G: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58: 29-33, 1998. (Pubitemid 28027711)
20. Yeh JJ, Marsh DJ, Zedenius J, Dwight T, Delbridge L, Robinson BG and Eng C: Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. Genes Chromosomes Cancer 26: 322-328, 1999. (Pubitemid 29529577)
21. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530, 1994. (Pubitemid 24173729)
22. Kim SH, Jung KC, Shin YK, Lee KM, Park YS, Choi YL, Oh KI, Kim MK, Chung DH, Song HG and Park SH: The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine. Histochem J 34: 97-103, 2002.
23. Chesneau V and Rosner MR: Functional human insulin-degrading enzyme can be expressed in bacteria. Protein Expr Purif 19: 91-98, 2000.
24. Espinosa R III, Lemons RS, Perlman RK, Kuo WL, Rosner MR and Le Beau MM: Localization of the gene encoding insulin-degrading enzyme to human chromosome 10, bands q23-q25. Cytogenet Cell Genet 57: 184-186, 1991.
25. Hooper NM: Families of zinc metalloproteases. FEBS Lett 354: 1-6, 1994.
26. Westermarck J and Kahari V-M: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999.
27. Foulon T, Cadel S, Prat A, Chesneau V, Hospital V, Segretain D and Cohen P: NRD convertase and aminopeptidase B: two processing metallopeptidases with a selectivity for basic residues. Ann Endocrinol (Paris) 58: 357-364, 1997. (Pubitemid 28081376)
28. Eggleson KK, Duffin KL and Goldberg DE: Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J Biol Chem 274: 32411-32417, 1999.
29. Mzhavia N, Berman YL, Qian Y, Yan L and Devi LA: Cloning, expression and characterization of human metalloprotease 1: a novel member of the pitrilysin family of metalloendoproteases. DNA Cell Biol 18: 369-380, 1999.
30. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RCP, Vekrellis K, Selkoe DJ, Saunders AJ and Tanzi RE: Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290: 2302-2303, 2000. (Pubitemid 32041570)
31. Chang LL, Stout LE, Wong WD, Buls JG, Rothenberger DA, Shier WT, Sorenson RL and Bai JPF: Immunohistochemical localization of insulin-degrading enzyme along the rat intestine, in the human colon adenocarcinoma cell line (Caco-2), and in human ileum. J Pharm Sci 86: 116-119, 1997.
32. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y and Enders GH: p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 119: 929-942, 2000.
33. Sun X-F: p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 8: 165-170, 2002.
34. Guan M, Peng H-X, Yu B and Lu Y: p73 overexpression and angiogenesis in human colorectal carcinoma. Jpn J Clin Oncol 33: 215-220, 2003.
35. Kapitanovic S, Cacev T, Berkovic M, Popovic-Hadzija M, Radosevic S, Seiwerth S, Spaventi S, Pavelic K and Spaventi R: nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma. J Clin Pathol 57: 1312-1318, 2005.
36. Jung JM, Bruner JM, Ruan S, Langford LA, Kyritsis AP, Kobayashi T, Levin VA and Zhang W: Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 11: 2021-2028, 1995. (Pubitemid 3000314)
37. Terashima M, Maesawa C, Oyama K, Ohtani S, Akiyama Y, Ogasawara S, Takagane A, Saito K, Masuda T, Kanzaki N, Matsuyama S, Hoshino Y, Kogure M, Gotoh, Shirane M and Mori K: Gene expression profiles in human gastric cancer: expression of maspin correlates with lymph node metastasis. Br J Cancer 92: 1130-1136, 2005.
38. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA and Cole GM: Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24: 11120-11126, 2004.
39. Kim DH, Yoon DS, Dooley WC, Nam ES, Ryu JW, Jung KC, Park HR, Sohn JH, Shin HS and Park YE: Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer. Histopathology 42: 37-42, 2003.
40. Docquier F, Farrar D, D'Arcy V, Chernukhin I, Robinson AF, Loukinov D, Vatolin S, Pack S, Mckay A, Harris RA, Dorricott H, O'Hare MJ, Lobanenkov V and Klenova E: Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 65: 5112-5122, 2005.
41. Medhioub M, Vaury C, Hamelin R and Thomas G: Lack of somatic mutation in the coding sequence of SIAH1 in tumors hemozygous for this candidate tumor suppressor gene. Int J Cancer 87: 794-797, 2000.
42. Singh S, Simon M, Meybohm I, Jantke I, Jonat W, Maass H and Goedde HW: Human breast cancer: frequent p53 allele loss and protein overexpression. Hum Genet 90: 635-640, 1993. (Pubitemid 23088073)
43. Jansson A and Sun XF: Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol 20: 811-816, 2002. (Pubitemid 34111390)
44. Ramirez-Montagut T, Blachere NE, Sviderskaja EV, Bennett DC, Rettig WJ, Garin-Chesa P and Houghton AN: FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 23: 5435-5446, 2004. (Pubitemid 39044054)
45. Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT and Nanus DM: Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cells. Clin Cancer Res 7: 1370-1377, 2001. (Pubitemid 32708694)
46. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW and Band V: The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58: 4782-4786, 1998.
47. Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R, Georgescu MM and Nanus DM: Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 5: 67-78, 2004.
48. Radu A, Neubauer V, Akagi T, Hanafusa H and Georgescu MM: PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 23: 6139-6149, 2003.
49. Skytt A, Strömqvist M and Egelrud T: Primary substrate specificity of recombinant human stratum corneum chymotryptic enzyme. Biochem Biophys Res Commun 211: 586-589, 1995.
50. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, De Las Casas LF, Roman JJ, Anfossi S, O'Brien T and Pecorelli S: The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol 94: 283-288, 2004.
51. Wagner SN, Atkinson MJ, Wagner C, Höfler H, Schmitt M and Wilhelm O: Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem Cell Biol 105: 53-60, 1996.
52. Radulescu RT, Zhang BY, Wilmanns W and Nüssler V: Human P-glycoprotein/Mdr1-gene product: surprising potential for nuclear localization and coupling to intracellular growth factor signalling. In: Acute Leukemias VII-Experimental Approaches and Novel Therapies. Springer-Verlag Berlin Heidelberg, pp454-455, 1998.